BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
Songbirds swap colorful plumage genes across species lines among their evolutionary neighbors- Study reveals how fast weight returns after ending GLP-1 drugs
- The Best 15 Applications for Efficiency and Association
- EU health regulator urges immediate vaccinations amid early surge in flu cases
- Finding China: Four Urban areas for a Remarkable Excursion
- How color-changing, bacteria-infused spacesuits could help keep future astronauts safe from space radiation
- RFK Jr.'s diet guidelines emphasize red meat, full-fat dairy. How healthy are they?
- Kidneys from Black donors are more likely to be thrown away − a bioethicist explains why
- Top 20 Wellbeing and Wellness Applications for a Sound Way of life
